280 related articles for article (PubMed ID: 28559462)
21. Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma.
Cheung IY; Feng Y; Vickers A; Gerald W; Cheung NK
J Mol Diagn; 2007 Apr; 9(2):237-41. PubMed ID: 17384216
[TBL] [Abstract][Full Text] [Related]
22. LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis.
Dorneburg C; Fischer M; Barth TFE; Mueller-Klieser W; Hero B; Gecht J; Carter DR; de Preter K; Mayer B; Christner L; Speleman F; Marshall GM; Debatin KM; Beltinger C
Clin Cancer Res; 2018 Nov; 24(22):5772-5783. PubMed ID: 29925504
[No Abstract] [Full Text] [Related]
23. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
[TBL] [Abstract][Full Text] [Related]
24. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
Cheung IY; Sahota A; Cheung NK
Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
[TBL] [Abstract][Full Text] [Related]
25. High-sensitivity immunocytologic analysis of neuroblastoma cells in paired blood and marrow samples.
Faulkner LB; Tintori V; Tamburini A; Paoli A; Garaventa A; Viscardi E; Tucci F; Lippi AA; De Bernardi B; Bernini G
J Hematother; 1998 Aug; 7(4):361-6. PubMed ID: 9735867
[TBL] [Abstract][Full Text] [Related]
26. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
[No Abstract] [Full Text] [Related]
27. The role of β-catenin and paired-like homeobox 2B (PHOX2B) expression in neuroblastoma patients; predictive and prognostic value.
El-Shazly SS; Hassan NM; Abdellateif MS; El Taweel MA; Abd-Elwahab N; Ebeid EN
Exp Mol Pathol; 2019 Oct; 110():104272. PubMed ID: 31220430
[TBL] [Abstract][Full Text] [Related]
28. Image-Guided Biopsy for Relapsed Neuroblastoma: Focus on Safety, Adequacy for Genetic Sequencing, and Correlation of Tumor Cell Percent With Quantitative Lesion MIBG Uptake.
Samoyedny A; Srinivasan A; States L; Mosse YP; Alai E; Pawel B; Pogoriler J; Shellikeri S; Vatsky S; Acord M; Escobar F; Edgar JC; Maris JM; Cahill AM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250393
[TBL] [Abstract][Full Text] [Related]
29. Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.
Yáñez Y; Grau E; Oltra S; Cañete A; Martínez F; Orellana C; Noguera R; Palanca S; Castel V
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1263-72. PubMed ID: 21706131
[TBL] [Abstract][Full Text] [Related]
30. [The TH, ELAVL4 and GD2 gene expression as diagnostic markers of bone marrow lesions in patients with neuroblastoma].
Druĭ AE; Tsaur GA; Popov AM; Tuponogov SN; Shorikov EV; Tsvirenko SV; Savel'ev LI; Fechina LG
Vopr Onkol; 2012; 58(4):514-20. PubMed ID: 23607207
[TBL] [Abstract][Full Text] [Related]
31. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
32. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
33. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
34. Bone and bone marrow involvement in neuroblastoma: A case report.
Huang C; Jiang S; Liao X; Li Y; Li S; Yang J
Medicine (Baltimore); 2020 Oct; 99(40):e22505. PubMed ID: 33019449
[TBL] [Abstract][Full Text] [Related]
35. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
[TBL] [Abstract][Full Text] [Related]
37. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies.
Cheung NK; Von Hoff DD; Strandjord SE; Coccia PF
J Clin Oncol; 1986 Mar; 4(3):363-9. PubMed ID: 3081691
[TBL] [Abstract][Full Text] [Related]
38. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.
Claudiani F; Stimamiglio P; Bertolazzi L; Cabria M; Conte M; Villavecchia GP; Garaventa A; Lanino E; De Bernardi B; Scopinaro G
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):21-4. PubMed ID: 9002744
[TBL] [Abstract][Full Text] [Related]
39. Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis.
Corrias MV; Parodi S; Tchirkov A; Lammens T; Vicha A; Pasqualini C; Träger C; Yáñez Y; Dallorso S; Varesio L; Luksch R; Laureys G; Valteau-Couanet D; Canete A; Pöetschger U; Ladenstein R; Burchill SA
Pediatr Blood Cancer; 2018 Jul; 65(7):e27052. PubMed ID: 29603574
[TBL] [Abstract][Full Text] [Related]
40. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]